Emergent BioSolutions Stock

Emergent BioSolutions EBIT

The EBIT of Emergent BioSolutions (EBS) as of Aug 13, 2026 is 142.10 M USD. In the previous year, EBIT was -71.90 M USD — a change of -297.64% (higher).

EBIT

142.10 MUSD

YoY

-297.64%

Last updated:

In 2026, Emergent BioSolutions's EBIT was 142.10 M USD, a -297.64% increase from the -71.90 M USD EBIT recorded in the previous year.

The Emergent BioSolutions EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2022
-181.70 base
Jan 1, 2023
-168.10 base
Jan 1, 2024
-71.90 base
Jan 1, 2025
142.10 base
Jan 1, 2026 (e)
14.79 base
Jan 1, 2027 (e)
18.00 base
Jan 1, 2028 (e)
17.73 base
Jan 1, 2029 (e)
19.43 base
YEAREBIT (M USD)
2029 est 19.43
2028 est 17.73
2027 est 18.00
2026 est 14.79
2025 142.10
2024 -71.90
2023 -168.10
2022 -181.70
2021 341.40
2020 438.50
2019 150.90
2018 89.80
2017 124.30
2016 94.70
2015 141.51
2014 89.19
2013 42.80
2012 36.56
2011 32.10
2010 73.56
2009 40.15
2008 29.93
2007 33.09
2006 38.03
Access this data via the Eulerpool API

Emergent BioSolutions Revenue

Emergent BioSolutions Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
1.12 B USD
-181.70 M USD
-211.60 M USD
Jan 1, 2023
1.05 B USD
-168.10 M USD
-760.50 M USD
Jan 1, 2024
1.04 B USD
-71.90 M USD
-190.60 M USD
Jan 1, 2025
742.90 M USD
142.10 M USD
52.60 M USD
Jan 1, 2026 (e)
733.05 M USD
14.79 M USD
17.22 M USD
Jan 1, 2027 (e)
892.00 M USD
18.00 M USD
48.23 M USD
Jan 1, 2028 (e)
878.60 M USD
17.73 M USD
22.79 M USD
Jan 1, 2029 (e)
963.20 M USD
19.43 M USD
47.70 M USD

Emergent BioSolutions Margins

Emergent BioSolutions stock margins

The Emergent BioSolutions margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Emergent BioSolutions. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Emergent BioSolutions.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
42.33 %
-16.26 %
-18.94 %
Jan 1, 2023
34.31 %
-16.02 %
-72.48 %
Jan 1, 2024
35.97 %
-6.89 %
-18.26 %
Jan 1, 2025
47.19 %
19.13 %
7.08 %
Jan 1, 2026 (e)
47.19 %
2.02 %
2.35 %
Jan 1, 2027 (e)
47.19 %
2.02 %
5.41 %
Jan 1, 2028 (e)
47.19 %
2.02 %
2.59 %
Jan 1, 2029 (e)
47.19 %
2.02 %
4.95 %

Emergent BioSolutions Stock analysis

What does Emergent BioSolutions do? Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Emergent BioSolutions's EBIT

Emergent BioSolutions's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Emergent BioSolutions's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Emergent BioSolutions's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Emergent BioSolutions’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Emergent BioSolutions stock

EBIT of Emergent BioSolutions is 142.10 M USD in 2026.

EBIT of Emergent BioSolutions changed from -71.90 M USD to 142.10 M USD, representing a -297.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Emergent BioSolutions since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Emergent BioSolutions historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Emergent BioSolutions

All Key Metrics — Emergent BioSolutions